We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Roquefort Therapeutics plc (ROQ) ORD GBP0.01

Sell:4.30p Buy:4.40p 0 Change: 0.55p (14.47%)
Market closed |  Prices as at close on 26 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:4.30p
Buy:4.40p
Change: 0.55p (14.47%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:4.30p
Buy:4.40p
Change: 0.55p (14.47%)
Market closed |  Prices as at close on 26 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Roquefort Therapeutics PLC is a biotechnology company. The Company is focused on developing pre-clinical medicines focused on treating hard-to-treat cancers. The Company’s portfolio consists of five fully funded, patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines includes Midkine antibodies with in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with in vivo efficacy, and MK cell therapy with direct and NK-mediated anti-cancer action. The Company operates through its subsidiaries Lyramid Pty Ltd (Lyramid) and Oncogeni Ltd. Lyramid is engaged in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression). Oncogeni Ltd has developed two families of cell and RNA oncology medicines.

Contact details

Address:
85 Great Portland Street,, First Floor
LONDON
W1W 7LT
United Kingdom
Telephone:
+44 (020) 39188633
Website:
https://www.roquefortplc.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 27 September 2024 27/09/24
AGM 27 June 2024 27/06/24
Final results 26 April 2024 26/04/24
Annual report 26 April 2024 26/04/24

General stock information

EPIC:
ROQ
ISIN:
GB00BMDQ2T15
Market cap:
£5.90 million
Shares in issue:
135.74 million
Sector:
No specific Industry
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Stephen West
    Executive Chairman of the Board
  • Ajan Reginald
    Chief Executive Officer, Director
  • Martin Evans
    Chief Scientific Officer, Director
  • Graham Robertson
    Vice President - Drug Discovery
  • Sabena Sultan
    Vice President - Drug Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.